Caligan Partners LP lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 43.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,583,585 shares of the biotechnology company's stock after selling 2,015,152 shares during the period. BioCryst Pharmaceuticals makes up approximately 6.2% of Caligan Partners LP's portfolio, making the stock its 7th biggest holding. Caligan Partners LP owned 1.25% of BioCryst Pharmaceuticals worth $19,635,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. CWM LLC boosted its position in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after buying an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,322 shares during the last quarter. nVerses Capital LLC bought a new position in BioCryst Pharmaceuticals during the second quarter valued at about $63,000. Finally, DRW Securities LLC purchased a new stake in BioCryst Pharmaceuticals during the second quarter worth about $74,000. 85.88% of the stock is owned by institutional investors.
BioCryst Pharmaceuticals Price Performance
Shares of NASDAQ:BCRX remained flat at $7.50 during trading on Friday. 773,932 shares of the stock were exchanged, compared to its average volume of 2,521,353. The company has a 50 day moving average price of $7.60 and a two-hundred day moving average price of $7.30. The stock has a market cap of $1.55 billion, a PE ratio of -12.29 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the company earned ($0.19) EPS. The firm's revenue was up 35.1% compared to the same quarter last year. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.
Analyst Ratings Changes
A number of research firms have weighed in on BCRX. Needham & Company LLC reiterated a "buy" rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Finally, JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.60.
Check Out Our Latest Stock Report on BCRX
BioCryst Pharmaceuticals Company Profile
(
Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Further Reading
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
